CV Sciences (CVSI) Net Cash Flow (2011 - 2026)
CV Sciences (CVSI) reported Net Cash Flow of $30000.0 for Q1 2026, down 91.64% on a YoY basis from $359000.0 in Q1 2025, and up 158.82% sequentially from -$51000.0 in Q4 2025.
CV Sciences (CVSI) Net Cash Flow (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Net Cash Flow data on file, last reported at $30000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow fell 91.64% year-over-year to $30000.0; the trailing twelve-month figure through Mar 2026 stood at -$501000.0 (down 421.15% YoY), and the FY2025 full-year result was -$172000.0, up 79.93% from the prior year.
- Net Cash Flow grew to $30000.0 in Q1 2026, from -$51000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.1 million in Q1 2022 to a low of -$1.3 million in Q2 2022.
- A 5-year average of -$62176.5 and a median of -$47000.0 in 2023 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 1168.09% in 2024, while the deepest fall reached 734.95% in 2024.
- Tracing CVSI's Net Cash Flow over 5 years: stood at -$528000.0 in 2022, then soared by 38.26% to -$326000.0 in 2023, then slumped by 59.82% to -$521000.0 in 2024, then surged by 90.21% to -$51000.0 in 2025, then jumped by 158.82% to $30000.0 in 2026.
- Business Quant data shows CVSI's Net Cash Flow at $30000.0 in Q1 2026, -$51000.0 in Q4 2025, and -$551000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Sep 30, 2025 | -551,000.00 |
| Sep 30, 2025 | -551,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | -521,000.00 |
| Dec 31, 2024 | -521,000.00 |
| Sep 30, 2024 | 502,000.00 |
| Sep 30, 2024 | 502,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -654,000.00 |
| Mar 31, 2024 | -654,000.00 |
| Dec 31, 2023 | -326,000.00 |
| Dec 31, 2023 | -326,000.00 |